Health Canada announced it was aware that the probable human carcinogen NDMA (N-nitrosodimethylamine) has been detected at unsafe levels in some Zantac (ranitidine) products, and the agency is closely assessing the issue with other drug regulators internationally, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). “The Department will take action as needed, and will keep Canadians informed,” the agency said in a news release.

The news comes just weeks after Health Canada announced yet another recall of Zantac products after NDMA was found at unacceptable levels.

On April 1, the FDA ordered the withdrawal of all Zantac products from U.S. shelves after reviewing studies that showed levels of NDMA could increase in the heartburn medication even under normal storage conditions, such as when it is exposed to higher temperatures or the longer amount of time it is from the manufacture date.

On June 26, the EMA suspended the sale of all Zantac products in the European Union due to the presence of NDMA and the health concerns the impurity posed to consumers.

We're here to help!

At Clark & DiStefano we are attentive, always focusing on the needs of our clients. We develop strategies that are tailored to each individual case, and we treat our clients as strategic partners in achieving a common goal. We endeavor to think outside of the box and formulate cost-effective strategies. Lastly, we believe in prompt communications with clients so they have predictability for reserve setting and sufficient time for studied pre-trial evaluations and recommendations.